Neonatal ibuprofen exposure and bronchopulmonary dysplasia in extremely premature infants

J Perinatol. 2020 Jan;40(1):124-129. doi: 10.1038/s41372-019-0444-4. Epub 2019 Aug 7.

Abstract

Objective: To evaluate the association of ibuprofen exposure with the risk of bronchopulmonary dysplasia (BPD) in extremely premature infants.

Study design: This was a retrospective study of all extremely premature infants admitted to a tertiary unit from 2016 to 2018.

Results: A total of 203 extremely premature infants were included in this study. The rate of BPD was significantly higher in infants with early exposure to ibuprofen (42.5%) compared to infants with no exposure (21.6%, P = 0.001). After adjusting for covariates, the risk of BPD was associated independently with ibuprofen exposure (odds ratios (OR) 2.296, 95% confidence interval (CI): 1.166-4.522, p = 0.016). Further analysis showed a trend towards higher risk of BPD in infants with successful patent ductus arteriosus (PDA) closure after ibuprofen treatment (32.3%) compared to non-treated infants (20.2%, p = 0.162).

Conclusion: Our findings suggest that ibuprofen exposure may contribute to the occurrence of BPD in extremely preterm infants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Birth Weight
  • Bronchopulmonary Dysplasia / chemically induced*
  • Confounding Factors, Epidemiologic
  • Ductus Arteriosus, Patent / drug therapy
  • Female
  • Gestational Age
  • Humans
  • Ibuprofen / adverse effects*
  • Ibuprofen / therapeutic use
  • Infant, Extremely Premature*
  • Infant, Newborn
  • Male
  • Pulmonary Surfactants / therapeutic use
  • Regression Analysis
  • Retrospective Studies
  • Risk Factors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Pulmonary Surfactants
  • Ibuprofen